Literature DB >> 22538784

[Geriatric multimorbidity in claims data - part 2 : diagnoses of hospitals and diagnoses from physicians in the ambulatory setting].

M Meinck1, N Lübke, F Ernst.   

Abstract

BACKGROUND: Due to demographics, characteristic multimorbidity in geriatric patients is resulting in increased social, medical, and healthcare challenges. Geriatric multimorbidity (GM) can be defined as the simultaneous occurrence of at least two diseases that require medical care with an interdisciplinary focus on independence in activities of daily living. Typical conditions of GM are, e.g., incontinence, cognitive impairment, frailty, and decubitus.
MATERIAL AND METHODS: Part 2 of this study is based on claims data of 240,502 AOK insurants (AOK is one of the major health insurance companies of the German statutory health insurance system) aged ≥ 60 years with at least one admission to a hospital with a geriatric ward. Geriatric conditions (GCs) were ascertained in two ways: diagnoses from physicians in the ambulant care setting and diagnoses in a hospital setting in 2008. A total of 15 GC were assessed using diagnoses based on ICD-10 codes (as per suggestion from scientific geriatric societies). An insurant was defined as a person with GM, if he/she had at least two GCs.
RESULTS: The proportion of GCs in ambulant or inpatient diagnoses of 240,502 insurants varied significantly in most cases. For specific GCs, considerably higher proportions of ambulant diagnoses (e.g., pain, impairment of vision, or hearing) or for inpatient diagnoses (e.g., electrolyte or fluid metabolism disorders, malnutrition, incontinence) were identified. Only on rare occasions were small differences observed comparing the proportions of specific GCs in the diagnoses of the two different care sectors. This finding reduces considerably the accordance between the two care sectors with reference to the presence or absence of a GC for ambulant or inpatient diagnoses. The main agreement was with the non-coding of specific GCs, not with ambulant or inpatient diagnoses. Insurants with a geriatric hospital admission or certain care level (level ≥ 1) generally had higher proportions for specific GCs for inpatient and ambulant diagnoses than non-geriatric treated insurants or insurants without a certain care level. Of the geriatric treated insurants and those with certain care levels, 90% were characterized by the presence of GM for both ambulant or inpatient diagnoses. This percentage is remarkably higher than for patients who featured no geriatric treatment or had no certain care level.
CONCLUSION: The inclusion of ambulant diagnoses in addition to inpatient diagnosis offers comprehensive possibilities to identify insurants with GM in claims data. The contribution of the diagnoses of both care sectors for the identification of GC and GM varies with regard to attribute and insurant orientation. Furthermore, significant attribute-oriented overlap of insurants claiming geriatric treatments and insurants with certain care levels became visible, which can open new possibilities for simpler identification of a portion of patients with GM.

Entities:  

Mesh:

Year:  2012        PMID: 22538784     DOI: 10.1007/s00391-012-0302-x

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN: 0948-6704            Impact factor:   1.281


  7 in total

Review 1.  How to measure comorbidity. a critical review of available methods.

Authors:  Vincent de Groot; Heleen Beckerman; Gustaaf J Lankhorst; Lex M Bouter
Journal:  J Clin Epidemiol       Date:  2003-03       Impact factor: 6.437

2.  [Geriatric multimorbidity in claims data - part 1. Analysis of hospital data and long-term care insurance data].

Authors:  N Lübke; M Meinck
Journal:  Z Gerontol Geriatr       Date:  2012-08       Impact factor: 1.281

3.  Identification of adverse drug events: the use of ICD-10 coded diagnoses in routine hospital data.

Authors:  Jürgen Stausberg; Joerg Hasford
Journal:  Dtsch Arztebl Int       Date:  2010-01-15       Impact factor: 5.594

4.  [Expansion or reduction of geriatric care structures in Germany? A critical analysis on the significance of the official statistics and other surveys].

Authors:  M Meinck; N Lübke; A Plate
Journal:  Z Gerontol Geriatr       Date:  2006-12       Impact factor: 1.281

5.  Operationalizing multimorbidity and autonomy for health services research in aging populations--the OMAHA study.

Authors:  Martin Holzhausen; Judith Fuchs; Markus Busch; Andrea Ernert; Julia Six-Merker; Hildtraud Knopf; Ulfert Hapke; Beate Gaertner; Ina Kurzawe-Seitz; Roswitha Dietzel; Nadine Schödel; Justus Welke; Juliane Wiskott; Matthias Wetzstein; Peter Martus; Christa Scheidt-Nave
Journal:  BMC Health Serv Res       Date:  2011-02-25       Impact factor: 2.655

6.  Which chronic diseases and disease combinations are specific to multimorbidity in the elderly? Results of a claims data based cross-sectional study in Germany.

Authors:  Hendrik van den Bussche; Daniela Koller; Tina Kolonko; Heike Hansen; Karl Wegscheider; Gerd Glaeske; Eike-Christin von Leitner; Ingmar Schäfer; Gerhard Schön
Journal:  BMC Public Health       Date:  2011-02-14       Impact factor: 3.295

7.  Prevalence estimates of multimorbidity: a comparative study of two sources.

Authors:  Martin Fortin; Catherine Hudon; Jeannie Haggerty; Marjan van den Akker; José Almirall
Journal:  BMC Health Serv Res       Date:  2010-05-06       Impact factor: 2.655

  7 in total
  3 in total

1.  [Geriatric multimorbidity in claims data - part 1. Analysis of hospital data and long-term care insurance data].

Authors:  N Lübke; M Meinck
Journal:  Z Gerontol Geriatr       Date:  2012-08       Impact factor: 1.281

Review 2.  [Geriatrics - an interdisciplinary challenge].

Authors:  Roland Nau; Marija Djukic; Manfred Wappler
Journal:  Nervenarzt       Date:  2016-06       Impact factor: 1.214

3.  [Geriatric multimorbidity in claims data: part 3: prevalence and predictive power of geriatric conditions in an age-specific systematic sample].

Authors:  M Meinck; N Lübke
Journal:  Z Gerontol Geriatr       Date:  2013-10       Impact factor: 1.281

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.